Macleods Pharmaceuticals Ltd. IPO Details
Macleods Pharmaceuticals was incorporated on June 5, 1989. The company is one of the leading, organically grown, wholly Promoter Group-owned, vertically integrated, global pharmaceutical companies based in India and is engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. It is 7th largest in the Indian pharmaceutical market by Domestic Sales for the six months ended September 30, 2021, and 2nd largest in the Covered Market in Fiscal 2021
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 60.5 M | - | - | ₹0 | DRHP DOC |
Macleods Pharmaceuticals Ltd. issue details
Macleods Pharmaceuticals Ltd. has 60.5 M shares on offer
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Macleods Pharmaceuticals Ltd. IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Macleods Pharmaceuticals Ltd. NUMBER OF SHARES ON OFFER
Macleods Pharmaceuticals Ltd. FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from operations (Rs in millions) | Cash Flow from operations (Rs in millions) | Free Cash flow (Rs in millions) | Margins |
| H1FY22 | 6,380.5 | 40,801.6 | 7,509.9 | 6,177.2 | 18.9% |
| FY21 | 20,228.4 | 71,994.2 | 12,684.6 | 7,544.2 | 29.1% |
| FY20 | 15,721.2 | 69,028.2 | 13,734.2 | 9,682.5 | 25.0% |
| FY19 | 14,234.6 | 58,704.4 | 6,942.1 | 5,553.5 | 22.8% |
Macleods Pharmaceuticals Ltd. INFORMATION ON IPO ISSUE
About Macleods Pharmaceuticals Ltd.
Macleods Pharmaceuticals was incorporated on June 5, 1989. The company is one of the leading, organically grown, wholly Promoter Group-owned, vertically integrated, global pharmaceutical companies based in India and is engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. It is 7th largest in the Indian pharmaceutical market by Domestic Sales for the six months ended September 30, 2021, and 2nd largest in the Covered Market in Fiscal 2021
Object of the Issue
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges
- Carry out the Offer for Sale of up to 60,482,040 Equity Shares by the Selling Shareholders
Macleods Pharmaceuticals Ltd. Strengths
Fast-growth
One of the leading and fast-growing companies with a significant presence in the IPM
Proven track record
Proven track record of building brands
Calibrated business model
Diversified presence across global markets with a calibrated business model
Involvement in global access
Environmental, social, and governance focused, including extensive involvement in global access
R&D-led differentiated portfolio
R&D-led differentiated portfolio of products and diversified and quality-compliant manufacturing capabilities
Macleods Pharmaceuticals Ltd. Risks
Issues regarding raw materials
The company may experience a shortfall in the supply of its raw materials or an increase in their prices
Limited number of markets
A significant portion of revenue from operations comes from a limited number of markets
Certain legal proceedings
Some of the company's Subsidiaries and certain of the promoters and directors are involved in certain legal proceedings
IPO FAQs
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.